New research in mice indicates that giving the diabetes drug rosiglitazone along with antimalarial drugs at the onset of cerebral malaria symptoms may improve survival and protect against cognitive defects (Serghides L et al. PLoS Pathog. 2014;10:e1003980).
A team of Canadian scientists reasoned that because both the malaria parasite and the host immune response to infection play roles in the development of malaria, adjunctive therapies that act on the host response may provide additional benefits to antiparasitic therapy. They found that compared with antimalarial therapy alone, adjunctive therapy with rosiglitazone—which has anti-inflammatory, antioxidant, and possible neuroprotective properties—was associated with reduced endothelial activation and enhanced expression of antioxidant enzymes and neuroprotective factors in the brains of infected mice.
Hampton T. Drug Combination Effective Against Malaria in Mice. JAMA. 2014;311(13):1282. doi:10.1001/jama.2014.3433